Page last updated: 2024-11-08

jacobine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

jacobine: RN given refers to (15alpha,20S)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID442741
CHEBI ID6080
MeSH IDM0061443

Synonyms (27)

Synonym
nsc-89936
12beta-hydroxy-12alpha,13beta-dimethylsenec-1-enine-15s-spiro-2'-(3'r-methyloxiran)
senecionan-11,16-dione, 15,20-epoxy-15,20-dihydro-12-hydroxy-, (15-alpha,20s)-
15,20-epoxy-15,20-dihydro-12-hydroxysenecionan-11,16-dione
hsdb 3500
(15alpha,20r)15,20-epoxy-15,20-dihydro-12-hydroxy-senecionan-11,16-dione
ccris 5777
nsc 89936
senecionan-11,16-dione, 15,20-epoxy-15,20-dihydro-12-hydroxy-, (15alpha,20r)-
(15alpha,20r)15,20-epoxy-15,20-dihydro-12-hydroxysenecionan-11,16-dione
brn 0054580
jacobine
unii-gm32u80h1r
gm32u80h1r ,
4-27-00-06827 (beilstein handbook reference)
jacobine.
CHEBI:6080
AKOS027326873
471-14-7
senecionan-11,16-dione, 15,20-epoxy-15,20-dihydro-12-hydroxy-, (15.alpha.,20s)-
jacobine [iarc]
spiro((1,6)dioxacyclododecino(2,3,4-gh)pyrrolizine-3(2h),2'-oxirane)-2,7(4h)-dione, 5,6,9,11,13,14,14a,14b-octahydro-6-hydroxy-3',5,6-trimethyl-, (2's,3's,5r,6r,14ar,14br)-
(2s,3s,5'r,6'r,9a1'r,14a'r)-6'-hydroxy-3,5',6'-trimethyl-5',6',9',9a1',11',13',14',14a'-octahydro-2'h-spiro[oxirane-2,3'-[1,6]dioxacyclododecino[2,3,4-gh]pyrrolizine]-2',7'(4'h)-dione
Q27107031
DTXSID501020078
CS-0084068
HY-124058

Research Excerpts

Overview

Jacobine (JAC) is a pyrolizidine alkaloid (PA) exhibiting adverse hepatic effects similar to those induced by another PA, monocrotaline.

ExcerptReferenceRelevance
"Jacobine (JAC) is a pyrolizidine alkaloid (PA) exhibiting adverse hepatic effects similar to those induced by another PA, monocrotaline (MCT). "( Genotoxicity of the pyrrolizidine alkaloid jacobine in rats.
Bowden, GT; Buhler, DR; Petry, TW; Sipes, IG; Sipes, KG, 1986
)
1.98

Toxicity

ExcerptReferenceRelevance
"Jacobine (JAC) is a pyrolizidine alkaloid (PA) exhibiting adverse hepatic effects similar to those induced by another PA, monocrotaline (MCT)."( Genotoxicity of the pyrrolizidine alkaloid jacobine in rats.
Bowden, GT; Buhler, DR; Petry, TW; Sipes, IG; Sipes, KG, 1986
)
1.98
"Pyrrolizidine alkaloids (PAs) are feeding deterrents and toxic compounds to generalist herbivores."( Toxicity of pyrrolizidine alkaloids to Spodoptera exigua using insect cell lines and injection bioassays.
Klinkhamer, PG; Leiss, KA; Nuringtyas, TR; van Oers, MM; Verpoorte, R, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrrolizine alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's3 (23.08)18.2507
2000's1 (7.69)29.6817
2010's5 (38.46)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.35 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index97.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]